Prediction of cardiovascular events by matrix metalloproteinase (MMP)-9 in elderly men

Thomas W. Weiss; Eline B. Furenes; Marius Trøseid; Svein Solheim; Elsa M. Hjerkinn; Ingebjorg Seljeflot; Harald Arnesen

doi:10.1160/TH09-05-0317

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(03): 679-681
DOI: 10.1160/TH09-05-0317

Letters to the Editor

Schattauer GmbH

Prediction of cardiovascular events by matrix metalloproteinase (MMP)-9 in elderly men

Thomas W. Weiss

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

²Third Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria

³Faculty of Medicine, University of Oslo, Norway

,

Eline B. Furenes

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

,

Marius Trøseid

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

,

Svein Solheim

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

,

Elsa M. Hjerkinn

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

,

Ingebjorg Seljeflot

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

³Faculty of Medicine, University of Oslo, Norway

,

Harald Arnesen

¹Centre for Clinical Heart Research and Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway

³Faculty of Medicine, University of Oslo, Norway

› Author Affiliations

Abstract

Full Text

References

References
1 Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol 2003; 26: 55-59.
2 Newby AC, George SJ, Ismail Y. et al. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost 2009; 101: 1006-1011.
3 Cicero AF, Derosa G, Manca M. et al. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 2007; 14: 193-198.
4 Derosa G, D’Angelo A, Ciccarelli L. et al. Matrix metalloproteinase-2, –9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227-231.
5 Derosa G, D’Angelo A, Tinelli C. et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007; 33: 129-134.
6 El Messal M, Beaudeux JL, Drissi A. et al. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 2006; 366: 185-189.
7 Hjerkinn EM, Abdelnoor M, Breivik L. et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 2006; 13: 325-333.
8 Furenes EB, Seljeflot I, Solheim S. et al. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand J Clin Lab Invest 2008; 68: 177-184.
9 Bermudez B, Lopez S, Pacheco YM. et al. Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res 2008; 79: 294-303.
10 Chakrabarti S, Patel KD. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J Leukoc Biol 2005; 78: 279-288.
11 Ruhul Amin AR, Senga T, Oo ML. et al. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta: a role for the dual signalling pathways, Akt and Erk. Genes Cells 2003; 8: 515-523.
12 Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333.